These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27222271)

  • 41. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
    Portron A; Jadidi S; Sarkar N; DiMarchi R; Schmitt C
    Diabetes Obes Metab; 2017 Oct; 19(10):1446-1453. PubMed ID: 28741871
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
    He YL; Serra D; Wang Y; Campestrini J; Riviere GJ; Deacon CF; Holst JJ; Schwartz S; Nielsen JC; Ligueros-Saylan M
    Clin Pharmacokinet; 2007; 46(7):577-88. PubMed ID: 17596103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.
    Stangier J; Su CA; Roth W
    J Int Med Res; 2000; 28(4):149-67. PubMed ID: 11014323
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.
    Pawsey S; Wood M; Browne H; Donaldson K; Christie M; Warrington S
    Drugs R D; 2016 Jun; 16(2):181-91. PubMed ID: 26987975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
    Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
    Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects.
    Astruc B; Tarral A; Dostert P; Mariotti F; Fabbri L; Imbimbo BP
    Br J Clin Pharmacol; 2005 Apr; 59(4):405-14. PubMed ID: 15801935
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
    Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
    J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of R1663, an oral factor Xa inhibitor, in healthy young subjects coupled with exploration of influence of gender and age.
    Schmitt C; Charoin-Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
    Thromb Haemost; 2012 Jul; 108(1):54-64. PubMed ID: 22552265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects.
    Xuan D; McBride S; Wastall P; Porcari A; DiCarlo L; Boyd RA
    Clin Pharmacol Drug Dev; 2016 Jan; 5(1):13-26. PubMed ID: 27119575
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects.
    Huntjens DRH; Ouwerkerk-Mahadevan S; Brochot A; Rusch S; Stevens M; Verloes R
    Clin Pharmacokinet; 2017 Nov; 56(11):1331-1342. PubMed ID: 28238203
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies.
    Kim TE; Gu N; Yoon SH; Cho JY; Park KM; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Feb; 34(2):482-94. PubMed ID: 22284902
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
    Hudkins RL; Raddatz R; Tao M; Mathiasen JR; Aimone LD; Becknell NC; Prouty CP; Knutsen LJ; Yazdanian M; Moachon G; Ator MA; Mallamo JP; Marino MJ; Bacon ER; Williams M
    J Med Chem; 2011 Jul; 54(13):4781-92. PubMed ID: 21634396
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects.
    Shi R; Honczarenko M; Zhang S; Fleener C; Mora J; Lee SK; Wang R; Liu X; Shevell DE; Yang Z; Wang H; Murthy B
    J Clin Pharmacol; 2017 Feb; 57(2):161-172. PubMed ID: 27402064
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers.
    Naik H; Vakilynejad M; Wu J; Viswanathan P; Dote N; Higuchi T; Leifke E
    J Clin Pharmacol; 2012 Jul; 52(7):1007-16. PubMed ID: 21610201
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probands.
    Renner A; Romanova J; Ferko B; Schmutz H; Nebolsin V; Müller M; Badorrek P; Marth K; Pohl W
    Pulm Pharmacol Ther; 2019 Dec; 59():101852. PubMed ID: 31597083
    [TBL] [Abstract][Full Text] [Related]  

  • 58. First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers.
    Van Eldik LJ; Sawaki L; Bowen K; Laskowitz DT; Noveck RJ; Hauser B; Jordan L; Spears TG; Wu H; Watt K; Raja S; Roy SM; Watterson DM; Guptill JT
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):131-143. PubMed ID: 32255549
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A mini review on biological activities of pyridazinone derivatives as antiulcer, antisecretory, antihistamine and particularly against histamine H3R.
    Asif M
    Mini Rev Med Chem; 2015; 14(13):1093-103. PubMed ID: 25429662
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker.
    Huynh C; Henrich A; Strasser DS; Boof ML; Al-Ibrahim M; Meyer Zu Schwabedissen HE; Dingemanse J; Ufer M
    Clin Pharmacol Ther; 2021 Jun; 109(6):1648-1659. PubMed ID: 33406277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.